Biliary Tumor drugs in development by stages, target, MoA, RoA, molecule type and key players, 2023

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Biliary Tumor and features dormant and discontinued products.

GlobalData tracks 22 drugs in development for Biliary Tumor by 22 companies/universities/institutes. The top development phase for Biliary Tumor is phase ii with nine drugs in that stage. The Biliary Tumor pipeline has 20 drugs in development by companies and two by universities/ institutes. Some of the companies in the Biliary Tumor pipeline products market are: Processa Pharmaceuticals, Mirati Therapeutics and Pharma Mar.

The key targets in the Biliary Tumor pipeline products market include Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274).

The key mechanisms of action in the Biliary Tumor pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with two drugs in Phase II. The Biliary Tumor pipeline products include six routes of administration with the top ROA being Oral and seven key molecule types in the Biliary Tumor pipeline products market including Small Molecule, and Monoclonal Antibody.

Biliary Tumor overview

Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms include jaundice, dark urine, abdominal pain, fever, itchy skin, nausea, vomiting, and unexplained weight loss. These signs, while indicative of bile duct cancer, may also stem from other conditions, emphasizing the importance of consulting a doctor for a thorough evaluation.

For a complete picture of Biliary Tumor’s pipeline drug market, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.